MPG.eBooks - Description: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Cover Image

Read Now

Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

The objective of this systematic review is to examine the beneficial and harmful effects of ocrelizumab treatment for the suppression of relapses and disease progression in adult patients with relapsing forms of multiple sclerosis (MS)

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH 2017, December 2017
Series:	CADTH common drug review clinical review report
Subjects:	Multiple Sclerosis, Relapsing-remitting / Drug Therapy Antibodies, Monoclonal, Humanized / Adverse Effects Treatment Outcome Antibodies, Monoclonal, Humanized / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534378
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this systematic review is to examine the beneficial and harmful effects of ocrelizumab treatment for the suppression of relapses and disease progression in adult patients with relapsing forms of multiple sclerosis (MS)
Item Description:	"Version 1.0."
Physical Description:	1 PDF file (118 pages) illustrations